An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: rituximab [Mabthera/Rituxan]

Study type: Observational

Funder types: Industry

Identifiers

NCT01075477

ML22609

Details and patient eligibility

About

This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis. Data from patients receiving MabThera according to local treatment guidelines will be collected for 29 months. Target sample size is 100-200 patients.

Enrollment: 151 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult patients, >/= 18 years of age
• rheumatoid arthritis
• treatment with rituximab

Exclusion criteria

• unable/unwilling to give informed consent to data collection

Trial design

151 participants in 1 patient group

Cohort

Treatment:

Drug: rituximab [Mabthera/Rituxan]